[제약사 리포트] 보령, 카나브 약가인하 문제 없다…1분기 영업익 반등

Boryeong's Q1 performance highlights the strategic resilience of pharmaceutical companies navigating government-mandated price reductions through legal action and conservative accounting. The outcome of the ongoing Kanarb lawsuit will serve as a significant industry benchmark for protecting the value of self-developed blockbuster drugs against regulatory pressure. This case underscores the importance of R&D-driven product portfolios in maintaining financial stability despite external policy volatility.